Altered contractility in mutation-specific hypertrophic cardiomyopathy: A mechano-energetic in silico study with pharmacological insights

Introduction: Mavacamten (MAVA), Blebbistatin (BLEB), and Omecamtiv mecarbil (OM) are promising drugs directly targeting sarcomere dynamics, with demonstrated efficacy against hypertrophic cardiomyopathy (HCM) in (pre)clinical trials. However, the molecular mechanism affecting cardiac contractility...

Descripción completa

Detalles Bibliográficos
Autores principales: Forouzandehmehr, Mohamadamin, Paci, Michelangelo, Koivumäki, Jussi T, Hyttinen, Jari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659818/
https://www.ncbi.nlm.nih.gov/pubmed/36388127
http://dx.doi.org/10.3389/fphys.2022.1010786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659818/
https://www.ncbi.nlm.nih.gov/pubmed/36388127
http://dx.doi.org/10.3389/fphys.2022.1010786

Ejemplares similares